Category Archives: Transhuman News

Jan. 13, 2021 13:35 UTC

REDWOOD CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, and Graphite Bio, Inc., a next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced a research and clinical collaboration agreement to evaluate JSP191, Jaspers first-in-class anti-CD117 monoclonal antibody, as a targeted, non-toxic conditioning regimen for Graphite Bios investigational GPH201 gene replacement therapy for severe combined immune deficiency (SCID) in patients with IL2RG deficiency, known as x-linked SCID (XSCID).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210113005538/en/

XSCID is a severe, inherited disorder of the immune system with symptoms often presenting in early infancy, including persistent infections and failure to thrive. Without treatment, XSCID is typically fatal to patients in the first two years of life.

Graphite Bio is focused on the development of potentially curative therapies for patients suffering from serious diseases, using its targeted gene integration platform to harness the natural cellular process of homology directed repair (HDR) in order to efficiently repair genetic defects at their source, deliver genetic cargo with precision and engineer new cellular effector functions. Jasper Therapeutics JSP191 is a first-in-class humanized monoclonal antibody that depletes hematopoietic stem cells from bone marrow and acts as a conditioning agent in patients prior to receiving a hematopoietic stem cell transplant. JSP191 is currently being evaluated in multiple trials as a stem cell depleting conditioning agent, including a Phase 1/2 trial to achieve donor stem cell engraftment in SCID patients undergoing hematopoietic cell transplant and a separate Phase 1/2 trial in AML/MDS patients undergoing hematopoietic cell transplant.

This collaboration with Jasper demonstrates our shared commitment to pioneering novel therapeutic approaches with the potential to significantly improve the treatment experiences of individuals with devastating conditions who stand to benefit from gene replacement therapies, initially for patients with XSCID, said Josh Lehrer, M.Phil., M.D., chief executive officer at Graphite Bio. GPH201 harnesses our targeted gene integration platform to precisely target the defective gene that causes XSCID and replace it with a normal copy. We are impressed by the initial positive clinical results demonstrated by JSP191 when used as a conditioning regimen, and look forward to collaborating with the Jasper team to explore how our novel technologies can be brought to more patients with XSCID and other indications.

Our collaboration with Graphite Bio is an exciting opportunity to further advance the field of curative gene correction by combining a targeted gene integration platform with our first-in-class targeted CD117 antibody, JSP191, that has already demonstrated preliminary clinical efficacy and safety as a conditioning agent in XSCID patients and those with blood cancers undergoing allogeneic hematopoietic stem cell transplant, said Bill Lis, executive chairman and CEO, Jasper Therapeutics.

Graphite Bio and Jasper will collaborate on research, and potentially a clinical study, evaluating JSP191 as a conditioning agent for GPH201. Each company will retain commercial rights to their respective technologies.

About JSP191

JSP191 (formerly AMG 191) is a first-in-class humanized monoclonal antibody in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow. JSP191 binds to human CD117, a receptor for stem cell factor (SCF) that is expressed on the surface of hematopoietic stem and progenitor cells. The interaction of SCF and CD117 is required for stem cells to survive. JSP191 blocks SCF from binding to CD117 and disrupts critical survival signals, causing the stem cells to undergo cell death and creating an empty space in the bone marrow for donor or gene-corrected transplanted stem cells to engraft.

Preclinical studies have shown that JSP191 as a single agent safely depletes normal and diseased hematopoietic stem cells, including in animal models of SCID, myelodysplastic syndromes (MDS) and sickle cell disease (SCD). Treatment with JSP191 creates the space needed for transplanted normal donor or gene-corrected hematopoietic stem cells to successfully engraft in the host bone marrow. To date, JSP191 has been evaluated in more than 90 healthy volunteers and patients.

JSP191 is currently being evaluated in two separate clinical studies in hematopoietic cell transplant. The first clinical study is evaluating JSP191 as a sole conditioning agent in a Phase 1/2 dose-escalation and expansion trial to achieve donor stem cell engraftment in patients undergoing hematopoietic cell transplant for severe combined immunodeficiency (SCID), which is potentially curable only by this type of treatment. JSP191 is also being evaluated in combination with another conditioning regimen in a Phase 1 study in patients with MDS or acute myeloid leukemia (AML) who are receiving hematopoietic cell transplant. For more information about the design of these clinical trials, visit http://www.clinicaltrials.gov (NCT02963064 and NCT04429191).

Additional studies are planned to advance JSP191 as a conditioning agent for patients with other rare and ultra-rare monogenic disorders and autoimmune diseases.

About GPH201

GPH201 is a first-in-human investigational hematopoietic stem cell treatment that will be evaluated as a potentially curative therapy for patients suffering from XSCID. GPH201 is generated using Graphite Bios precise and efficient targeted gene integration platform technology to directly replace the defective IL2RG gene, maintain normal IL2RG regulation and expression, and ultimately lead to the production of fully functional adaptive immune cells.

About Jasper Therapeutics

Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. The companys lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplant. This first-in-class conditioning antibody is designed to enable safer and more effective curative hematopoietic cell transplants and gene therapies. For more information, please visit us at jaspertherapeutics.com.

About Graphite Bio, Inc.

Graphite Bio is a next-generation gene editing company focused on the development of potentially curative therapies for patients suffering from serious diseases. The companys targeted gene integration platform harnesses the natural cellular process of homology directed repair (HDR) to efficiently repair genetic defects at their source, deliver genetic cargo with precision and engineer new cellular effector functions. Graphite Bio is leveraging its differentiated platform, initially focused on ex vivo engineering of hematopoietic stem cells, to advance a portfolio of transformative treatments with potential for saving and dramatically improving patients lives. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, MD, and Matthew Porteus, MD, PhD, and is backed by Versant Ventures and Samsara BioCapital. For more information, please visit graphitebio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005538/en/

Read more from the original source:
Jasper Therapeutics and Graphite Bio Announce Collaboration to Evaluate JSP191 as Conditioning Regimen for Novel Gene Replacement Therapy in Patients...

Others

It also provides accurate calculations and sales reports of the segments in terms of volume and value. The report introduces the industrial chain analysis, downstream buyers, and raw material sources along with the accurate insights of market dynamics. The report also studies the individual sales, revenue, and market share of every prominent vendor of the Genetic Engineering Market. It majorly focuses on manufacturing analysis including the raw materials, cost structure, process, operations, and manufacturing cost strategies. The report delivers detailed data of big companies with information about their revenue margins, sales data, upcoming innovations and development, business models, strategies, investments, and business estimations.

The Genetic Engineering Market reports deliver information about the industry competition between vendors through regional segmentation of markets in terms of revenue generation potential, business opportunities, demand & supply comparison taking place in the future. Understanding the Global perspective, the Genetic Engineering Market report introduces an aerial view by analyzing historical data and future growth rate.

Request customization of the report @https://reportsglobe.com/need-customization/?rid=28068

Genetic Engineering Market: By Region

North America Europe The Asia Pacific Latin America The Middle East and Africa

The objectives of the Genetic Engineering Global Market Study are:

Split the breakdown data by region, type, manufacturer, and application. Identify trends, drivers, and key influencing factors around the world and in the regions Analysis and study of global Genetic Engineering status and future forecast, including production, sales, consumption, history, and forecast. Analysis of the potential and advantage, opportunities and challenges, limitations, and risks of the global market and key regions. Analyze competitive developments such as expansions, agreements, product launches, and acquisitions in the market. Introducing the major Genetic Engineering manufacturers, production, sales, market share, and recent developments.

To learn more about the report, visit @ https://reportsglobe.com/product/global-genetic-engineering-market-size-study/

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe, or Asia.

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

Go here to see the original:
Genetic Engineering Market Size 2021 By Analysis, Manufacturers, Regions, Type and Application, and Forecasts to 2027 - Jumbo News

Given how House of El: The Shadow Threat's depicts Superman's parents, this really could have been a prequel to Zack Snyder's Man of Steel.

WARNING: The following contains spoilers for House of El: The Shadow Threat#1 by Claudia Gray, Eric Zawadski, Dee Cunniffe, and Deron Bennett, on sale now.

We've seen quite a few takes from DC on Krypton's society before it was destroyed, showing what life was like for Jor-El and Lara before they shot Kal-El off to Earth to save him. Outside of the mainstream continuity where Jor-El eventually returned to inform his son of their history, it was addressed in Elseworld stories such as All-Star Superman.These stories add layers of sympathy to the planet and show how the various clans suffered through their civil war--with bad choices made rampantly.

Now, the young-adult graphic novel, House of El: The Shadow Threat adds its own spin, but after dissecting what Superman's parents are up to here, this is actually the perfect prequel to Zack Snyder's Man of Steel.

RELATED:How House of El: The Shadow Threat Sets Up a Sequel

In the opening sequence to the DCEU movie, we witnessedRussell Crowe's Jor-El wanting more for his son, especially after the elites lost the plot on how to deal with the quakes that were occurring. General Zod and his military had also become disillusioned with their terraforming missions.Following an attempted coup it became clear Krypton was imploding from the inside long before the big bang.

But what stood out in Snyder's vision was how Krypton created its houses, with genetic engineering leading to predetermined fates for clans. This is how Krypton locked in artists, scientists, soldiers and politicians -- with people having fixed destiniesas their genes were assembled in chambers. Jor-El hated it because it meant no one could evolve and dream to be something bigger, thus there wouldn't be as many leaders and revolutionists. More so, natural birth for Kryptonianswas taboo, which is how Kal-El was made.

RELATED:Superboy: Conner Kent Gets a New Role in the Superman Family

The Shadow Threat walks a very similar path as Lara's created a machine that can scramble people's genetic code to make them complete Kryptonians. It's a re-sequencing to give them emotions such as compassion and empathy. This is her way of bettering society because the tribunes have created a nasty caste system. They're younger here so this would have beenthe perfect precursor to what Snyder laid down as it's adetailed look into how this was affecting the youth on Krypton, especially the military.

Granted, Lara's pregnant in this story through natural means, but had House of El simply not had her conceiving, it'd inform how Jor-El and Lara were on the big-screen and why they acted the way they did. Here, they'rerevolting outcasts that the tribunes don't want to deal with. As Lara's cousin, Zahn-Re, triesto figure out his destiny, his perspective reveals just how crazy Lara and Jor-El were considered. Even Sera-Ur, the soldier Lara reformats, thinks that while the couple's revered, they're best left on the fringes of Krypton.Thestory adds nuance as Lara mopes around temples, gathering intel on the old ways and who might still be interested.

There's also Midnight, an insurrectionist group that feels like they're made to follow General Zod in overthrowing the guilds. They want freedom and an equal Krypton, much like Zod's legion in Man of Steel. In the film, we learned he and Jor-El were close, and thisbook follows suit. In fact, Zod's the one who sends Sera to be reformatted secretly in Lara's lab.

While the filmversion of Zod is dedicated to order, his military duty and the Genesis Chamber for genetic coding, House of El has him toeing the line. He wants to liberate people, buthe also wants peopleto fall in line when he says so. It's easy to see him actually realizing genetic coding and the chamber workin his terrorist mission to produce brainwashed soldiers, which can be where he and the Els fell apart. Ultimately, there are quite a few parallels that just can't be ignored which could have beefed up what Snyder did.

KEEP READING:Superman: Who's REALLY Running the Daily Planet Now

Valkyrie: Everyone Who's Been Marvel's OTHER Asgardian Avenger

I'm a former Chemical Engineer. It was boring so I decided to write about things I love. On the geek side of things, I write about comics, cartoons, video games, television, movies and basically, all things nerdy. I also write about music in terms of punk, indie, hardcore and emo because well, they rock! If you're bored by now, then you also don't want to hear that I write for ESPN on the PR side of things. And yes, I've written sports for them too! Not bad for someone from the Caribbean, eh? To top all this off, I've scribed short films and documentaries, conceptualizing stories and scripts from a human interest and social justice perspective. Business-wise, I make big cheddar (not really) as a copywriter and digital strategist working with some of the top brands in the Latin America region. In closing, let me remind you that the geek shall inherit the Earth. Oh, FYI, I'd love to write the Gargoyles movie for Disney. YOLO.

Read more here:
House of El: The Shadow Threat is The Perfect Man of Steel Prequel - CBR - Comic Book Resources

German biotech Eleva has received funding to advance its candidate CPV-101, produced using a moss-based expression system.

Venture capitalist firm Zukunftshonds Heilbronn has invested up to 60 million ($73 million) in funding to progress drug candidate CPV-101 through the clinic. A spokesperson for Eleva told us we are developing CPV-101 for kidney-associated complement diseases such as aHUS, IgA Nephropathy, PNH, C3G.

The firm has developed a manufacturing process that produces biopharmaceuticals using moss called BryoTechnology.

Image: iStock/Svetlana Monyakova

Eleva told BioProcess Insider fermentation is done in Sartorius STR single use fermenters with unmodified cell culture bags and is done using established routines and equipment used commonly in mammalian cell-based production.

The company claims that BryoTechnology benefits from the absence of animal derived components and human viruses [] and batch to batch stability. Eleva added the manufacturing process is very robust and stable (unsensitive to change in pH, temp and salt). The glycosylation pattern is very stable, also upon scale up and tech transfer we do not see any changes in the glycosylation pattern.

Bjrn Voldborg, director of CHO cell line development at the Technical University of Denmark, previously discussed the problems that surround glycosylation at BPI Europe, telling delegates if you have the wrong glycans the protein may actually trigger immune responses.

Eleva said where glycosylation is crucial for the mode of action or for the efficacy of the molecule [it is] especially suited for the production in moss.

We have previously reported the limitations mammalian and bacterial cell lines have alongside documenting the growing interest in plant-derived alternatives.

Whatever system used, cells are engineered to produce the desired biologic drug substance in the highest yield and purity possible. Yet, with mammalian cell culture being notoriously expensive, plant-cells have become an alternative choice of platform due to their cost-effective expression system, free of animal proteins.

Eleva is not alone in its quest for plant-based substitutes, Sanofis deal with Dyadic showcased the demand for CHO alternatives. However, Eleva claims to be the only company using moss as an expression platform to make biologics.

Moss produces complex molecules (proteins, enzymes, antibodies, metabolites) with human-like glycosylation the spokesperson told us, adding antibodies produced in moss show >40-fold ADCC enhancement compared to antibodies produced in mammalian systems.

When asked what advantages a moss-based system has over mammalian, microbial and other plant-based systems, Eleva said moss combines the best of two worlds: it is a higher eukaryote same as mammalian cells and is haploid organism same as microbials.

The firm added: Contrary to other plant-based systems such as tobacco, moss has a haploid genome, making genetic engineering as easy as in microbials.

Read the original:
Moss-based expression firm receives 60m in funding - BioProcess Insider - BioProcess Insider

Robert Sheasby, CEO of the AIC, the voice of the UK feed and the agri-supply sector, said:

The AIC warmly welcomes the launch of this government consultation on gene editing in crops and livestock. We have long sought to support sustainable modern commercial agriculture in the UK, and this is the opportunity for our members to put forward their views on this development in technology. We would encourage the industry at large to respond.

EU legislation controlling the use of GMOs was retained in the UK at the end of the transition period, after December 31, 2020. This retained legislation requires that all GE organisms are classified as GMOs irrespective of whether they could be produced by traditional breeding methods.

The UK's Department of Food, Rural Affairs and the Environment (Defra) said it is its view that organisms produced by GE or by other genetic technologies should not be regulated as GMOs if they could have been produced by traditional breeding methods.

Leaving the EU provides an opportunity to consult on the implications of addressing this issue. We recognize there is a spectrum of opinions on these topics, and we are consulting to provide an opportunity for all views to be shared."

Speaking at the Oxford Farming Conference, where the consultation was launched, UK environment secretary, George Eustice, said:

Gene editing has the ability to harness the genetic resources that mother nature has provided, in order to tackle the challenges of our age. This includes breeding crops that perform better, reducing costs to farmers and impacts on the environment, and helping us all adapt to the challenges of climate change.Its potential was blocked by a European Court of Justice ruling in 2018, which is flawed and stifling to scientific progress. Now that we have left the EU, we are free to make coherent policy decisions based on science and evidence. That begins with this consultation.

Consulting with academia, environmental groups, the food and farming sectors and the public is the beginning of this process that, depending on the outcome, will require primary legislation scrutinized and approved by the UK parliament, stressed Defra.

Professor Robin May, the chief scientific officer of the UKs Food Standards Agency (FSA), also welcomed the review, saying:

The UK prides itself in having the very highest standards of food safety, and there are strict controls on GM crops, seeds and food which the FSA will continue to apply moving forward. As with all novel foods, GE foods will only be permitted to be marketed if they are judged to not present a risk to health, not to mislead consumers, and not have lower nutritional value than existing equivalent foods. We will continue to put the consumer first and be transparent and open in our decision-making. Any possible change would be based on an appropriate risk assessment that looks at the best available science.

Sir David Baulcombe, professor of botany in the Department of Plant Sciences at the University of Cambridge, said the overwhelming view of public sector scientists is that the Nobel Prize winning methods for gene editing can accelerate the availability of crops and livestock for sustainable, productive and profitable agriculture.

The UK National Pig Association (NPA) said that gene editing technology could potentially deliver long-term benefits for pig production.

In the NPA's response to the Nuffield Council of Bioethics call for evidence on genome editing in September 2019, its senior policy adviser, Rebecca Veale, identified the potential value of gene editing tools in improving the efficiency of pig production.

"The opportunities for application are long. We might be in a better place to tackle diseases such as ASF and PRRS and we might be able to reduce emissions in pig production or exploit nutritional availability in feed better.

"Afew countries have made small steps to utilizing this technology, but these have been limited. Our industry cannot be disadvantaged by a lack of access to such a tool and any future policy must be clear not to breach ethical boundaries, but to have flexibility to allow the use of the technology to be exploited to its full potential. Any future developments are reliant on support for the research required to explore the opportunities available, she added.

Responding to the consultation, the director of anti-GM campaign group, GM Freeze, Liz ONeill said:

"People have many concerns about the use of genetic engineering in food and farming so public engagement is vital but it has to be done well. Unfortunately this consultation has started very badly. Its been launched in the midst of an unprecedented health crisis; it has a clear bias in favour of removing vital safeguards; and the text of the consultation grossly misrepresents the nature of highly experimental new GM techniques.

"Instead of working with people to understand their concerns, Defra is pushing the high-tech, quick-fix agenda favoured by industrial farming corporations. GM Freeze will, of course, be submitting evidence and we encourage everyone who wants to know what they are eating to do the same, but the government should be doing much more to protect our food, our farms and the natural environment."

Aside from gene editing, the consultation will also begin a longer-term project to gather evidence on updating the UK approach to genetic modification by gathering information on what controls are needed and how best to deliver them, said Defra.

Read more:
UK feed and pig industries welcome UK consultation on gene editing - FeedNavigator.com

Scientists have created a living material made from microbes that can respond to stimuli from their surrounding environment. It is hoped the material could find diverse applications in contaminant detection, highlighting damage, for example, to packaging, delivering nutrients or therapeutics and even in creating living photographs.Biological systems are able to assemble and arrange tissues and structures, building in changes that reflect external stimuli, in ways beyond the capability of man-made materials. Consequently, the development of materials with these capabilities is highly desirable for monitoring purposes. Engineered living materials (ELMs) such as these have been created previously, however, the stringent growth conditions required for the microbes used have restricted their use to trained personnel. Scaling up production to facilitate their use as a technology has also consequently proved challenging. This latest research, published today in Nature Materials, however, overcomes these problems by taking its inspiration from the fermented drink kombucha.

Kombucha is a fermented culture of yeast and bacteria used to make a tea drink thought to have beneficial health properties. The kombucha mother culture from which the tea is made normally contains one or two strains of bacteria and at least two strains of yeast that live in symbiosis.

Scientists from Imperial College London and Massachusetts Institute of Technology combined genetically engineered bakers yeast - the yeast typically found in kombucha is hard to engineer - with cellulose-producing bacteria to create a mutually beneficial symbiotic culture. The Komagataeibacter rhaeticus bacteria used was isolated from a kombucha mother culture and produces large quantities of cellulose that acts as a scaffold to support multi-functional enzymes produced by the yeast.

The researchers were able to engineer the yeast according to the needs of their system, for example to produce enzymes that fluoresced or that broke down target molecules. The systems for genetically engineering bakers yeast are well established and fast, meaning that new strains with particular desired characteristics can be created quickly. The simple growth conditions required by the kombucha-style culture also mean that any new combination can quickly be established and bulked up ready for use. Both of these features make this a favorable ELM system.

In a press release, senior author Professor Tom Ellis from Imperial College London said, The genetic toolbox for engineering these bacteria is underdeveloped compared to the number of tools available for manipulating yeast DNA. That is why we chose to use this division-of-labor strategy so we could first focus on engineering the yeast cells and explore the possibilities of various living functional materials."

The malleable nature of the yeast engineering system gives it utility in many areas opens doors to adapting the system to many purposes. In the study, the team incorporated yeast capable of sensing estradiol, a hormone found as an environmental pollutant, but this is just one example of the many possible applications. The team foresee that it could even be used to deliver essential nutrients or release therapeutics in response to stimuli.

Although we are still far from a future in which people can cheaply grow their own biological sensors, our new system moves us forward by creating materials that are scalable and therefore more likely to be useful in the real world, commented Dr Charlie Gilbert, one of the studys authors.

ReferenceGilbert C et al. Living materials with programmable functionalities grown from engineered microbial co-cultures. Nat. Mater. (2021). https://doi.org/10.1038/s41563-020-00857-5

The rest is here:
Kombucha Inspires Creation of a Microbial Living Material - Technology Networks

A bold, but divided new Krypton reveals itself in House of El Book 1: The Shadow Threat. Stemming from DC's blooming YA line and headlined by New York Times bestselling author Claudia Gray and cult-favorite illustrator Eric Zawadzki, House of El introduces readers to the world beyond the world we think we know - before the birth of Superman.

Zahn and Sera are two Kryptonians who couldn't be more different. Zahn is a member of the upper crust of Krypton, on track to become one Krypton's lawmaking caste moving then into rule amongst his wealthy and affluent family members who make up one of the planet's most powerful. Sera is a soldier, undergoing missions for the government and restricted to only certain parts of the planet befitting her 'station.'

But when the two become aware of a secret the ruling families of the planet have kept hidden, a secret two Kryptonian scientists by the name of El are struggling to bring to light, they together are thrust into an adventure that has seismic repercussions for the planet and it's strict caste-based society that has driven them to this point.

Newsarama recently got a chance to talk to the creative team of House of El, discussing the process by which the series came about, the design elements of the book, and how the work of creating this Elseworlds-esque new Krypton actually went down. Join us as we enter this new House of El.

Newsarama: How did House of El first come about? Was it something commissioned by the Superman editorial office or was it something independently pitched?

Claudia Gray: Somewhere in-between, I think. I pitched something else, and while they didn't want to go in that direction, they liked the pitch enough to want to talk more about how we might work together. They had a very rough idea for a story about original characters set on Krypton before the explosion and let me run with it.

Nrama: How much design work was done from there? I would assume a large amount of character work was first up to nail down, but how was the look and feel of this particular Krypton developed?

Gray: My starting point for the look of Krypton was the Superman symbol itself - it's a Kryptonian design, so what could that tell me? So, I worked with a lot of angularity, enclosed lines, stronger colors.

And this is a planet that has gotten very far away from nature in every possible sense of the world, one that has ceased to be grounded - so that led to a take on Krypton as a hyper-industrialized, overbuilt planet where people largely live in towers and walkways far above the surface.

Everything after that is thanks to Eric Zawadzki, the brilliant artist who took those few elements and ran with it, creating something that surpassed my most optimistic hopes.

Nrama: Which brings us to Eric actually! Eric, how did your involvement with House of El start?

Eric Zawadzki: The original editor on the project, Alex Carr, had read an indie book of mine, Eternal. He seemed impressed enough with it to reach out to me about getting involved with House of El. Fortunately, I was winding down on Heart Attack at Skybound/Image Comics, so I jumped at the chance.

Nrama: Krypton itself has had a number of visual touchstones and tonalities over the years. How important was it for you that House of El stand out among them?

Zawadzki: Generally speaking, Krypton isn't shown much in media. It's usually the first five pages in a comic or the first 20 minutes of a movie before we move on to the main story. So, I thought it was a pretty big deal to do an entire trilogy of graphic novels devoted to Krypton.

So, I would say that I was very intimidated!

Nrama: Switching back to you, Claudia, we are provided a very divided Krypton in House of El. Both in the lead characters, one representing an "academic, noble house of Krypton" and the other providing a look into a lower born, more tactile Kryptonian life, but in the scene settings as well as readers will see both affluent and unsupported sections of Krypton.

How important was it to explore this dichotomy and was there any push/pull to make either side seem 'right'?

Gray: The dichotomy was essential. This is a planet whose people have completely lost the ability to communicate with each other outside of their houses and castes - the paths in life they're genetically programmed to follow.

Sera and Zahn should never have had any but the most glancing interactions, but the events of the story throw them together and, in the process, give them each a viewpoint on their world they'd never imagined.

There was definitely no need to make one side or another be 'right', because by this point in Krypton's history, every single side is wrong. Only a handful of individuals, from different houses, are able to see beyond the rigid structure of the society they're born into.

Nrama: Krypton also has a very distinct sense of fashion, but with House of El, you Eric bring a whole new level of sartorial chicness to the costumes, but one still clearly rooted in 'classic Kryptonian looks.' Can you talk a little about the process of costuming the cast?

Zawadzki: I found that in a lot of interpretations of Krypton, artists really leaned into the spandex approach, inspired by Superman's iconic costume. I have a little bit of that in this series, but I wanted to find some distinctive clothing themes to make this series different from everything before it.

Also, I was presented with the challenge of making sure the lower and upper castes were distinctive from each other. Generally speaking, I made sure the lower caste wore more functional, plain-looking outfits, while the upper castes tended to wear more outrageous, haute couture-inspired clothing.

Nrama: Claudia, how much research was done prior to starting active development?

I would imagine there would be some desire to make sure you don't overwrite anything already established by Kryptonian society, but at the same time House of El reads and feels so wholly like its own thing, I was curious to see if there were any major influences there.

Gray: My DC editors strongly encouraged us not to rely on past influences. They wanted us to write it as though it hadn't been written before. I'm so grateful for that--not only for the trust they showed in us, but also because, if I'd spent too much time looking at so many brilliant previous takes on it, I'd probably have been intimidated into a fatal case of writer's block.

Nrama: Eric, you also provide House of El a very dense, intricate architectural design. How did you even start to tackle the buildings and vehicles?

Zawadzki: There was a bit of a guidepost given to me by Claudia in how the city is built. (which you'll see in book 2) So I used that as a jumping-off point. The planet is built around hierarchy, so I challenged myself to do something different than what I'd seen many times in other media depicting a similar society.

I ended up designing the city as a series of platforms stacked on top of each other, with various walkways and stairs uniting them. Because Krypton has technology that creates and repairs these structures, I wanted a kind of uniform look where there are patterns of overlapping planks of metal that wrap around and grow on top of these structures. And, overall I just wanted to depict a vast, detailed city that feels alive.

Nrama: Claudia, how was this first volume scripted?

We know that this is the opening of a larger House of El series that readers will get to experience eventually, but was this first book written in a 'vacuum' to be enjoyed as its own start to finish story or was it all written into one longer sequence?

Gray: To me it feels very much like the first part of a trilogy - the last page should leave you wondering what happens next. It's such a huge thing to ask of readers, but hopefully they'll come along for the ride.

Nrama: With House of El being an original trilogy, was there any desire to make them all a followed through narrative? Meaning, was there any drive to add in little bits and bobs of story in Vol. 1 to pay off in later volumes, or was it more internally focused as you tackled each volume?

Gray: Honestly, it's one big story, told in three episodes that hopefully each feel like a complete adventure on their own. But the links and payoff are definitely both within each book and among all three of the books.

Nrama: Eric, you've also been paired up here with the wonderful colorist Dee Cunniffe, did you find yourself giving them a little visual 'runway' in the way you laid out various pages?

Zawadzki: I've worked with Dee several times in the past, so I was happy to have him on board. I always feel like he saves me, making my work look better than it actually is. I generally try to get out of his way and let him do his thing. He developed some new skills and a new style specifically for this project and I couldn't be happier with it!

Nrama: Though this series is an original, out-of-continuity take on Krypton, did you find yourself taking any visual cues from other Superman or Krypton based stories? I personally saw a lot of P. Craig Russell and Jerry Ordway in your artwork.

Zawadzki: I'm honored to be compared to such artistic heavyweights! I was very intimidated in the beginning and I like to be prepared, so when I was hired for the project, I saw it as my responsibility to do my research and view as many artistic interpretations of Krypton as possible.

I particularly enjoyed what John Byrne and Gene Ha visualized. But when I sent some early sketches to editorial, they made it very clear to me that they preferred that I made this as unique as possible and make it 100% my own. So from that point on, I stopped my research. I think it's a smart approach, being beholden to nothing from the past, as it provides an antithesis to the continuity-heavy main DC line of books.

Nrama: Claudia, let's talk about your leads. We are introduced early to Zahn (a member of the Scholar/Law Class) and Sera (a Kryptonian soldier), both working strictly within their casted assignments on Krypton, but how were they conceptualized at first?

Did you come at them first from their ideological standpoints first or was it a matter of thinking what Kryptonian youth would feel/act like?

Gray: They both sprang out of the core concept of genetic engineering, of a society that essentially bred its children to be exactly what their parents expected, exactly what their parents were themselves. So that meant both characters very much needed to be exemplars of a very certain type of programming, something that would be instantly relatable to the reader.

From that, it became, okay, which segments of society should they belong to in order to best further the story? I needed people in dramatic positions - and I also needed to create links to the canonical characters of Jor-El, Lara, and Zod. So, Zahn became a relative of Lara's, and Sera became a minion of Zod's.

Nrama: As with most Krypton related stories, House of El carries a heavy sense of dread throughout the whole first volume. Was this intentional or just a happy accident since you were already dealing with DC's most famous doomed planet?

Gray: It's definitely intentional. Zahn and Sera are discovering just how much genetic engineering has wounded their society - and, inevitably, that's going to lead to the ultimate expression of that, i.e., Krypton's inability to understand that it's doomed in time to save its people.

Nrama: Eric, you also wonderfully parse the rapidly changing climate and look of the environment of Krypton. Did you have to set these pages or sequences apart from the 'main' action of the piece or just take it on as the pages arrived?

Zawadzki: I was given a 180-page completed script when I signed on to the project, which is unlike anything I've worked on prior. Usually, I'm only given 20 or so pages at a time. This allowed me to prepare for sequences months in advance of working on them.

Unfortunately, there's just never enough time. Especially when you're designing an entire world and culture! So I basically take it page by page and do my best. If it were entirely up to me, I'd probably still be doing design and prep work to make things much better. And the books would never come out! Which is why deadlines are good for me.

Nrama: So with this being the opening of the House of El trilogy, what else can we expect at least visually from the rest of the volumes? No Spoilers, of course!

Zawadzki: Expect to see more destruction and see more of how Krypton works. And I have to say, I had a lot of fun on book two illustrating our two leads getting to know each other better. Lots of great acting opportunities given to me by my brilliant partner in crime, Claudia Gray!

Nrama: Claudia, early on in Book 1, Sera is faced directly with the caste system and her "inferior" station on the planet compared to "the elite" society of Krypton, but displays almost a radical empathy and almost pity toward the people she protects, calling herself the "shield that protects Kryptonians from everything".

To me, this sounds VERY Superman but with a stronger sense of civic pride. Were there moments throughout the scripting of this series where you thought "What would Kal-El do or think?" in these situations?

Gray: No, I didn't think too much about that--because, as Jor-El and Lara make clear (spoilers ahoy!), Superman does not share the genetically programmed elements of Krypton. They conceived him naturally. So while he obviously has some of his parents' traits, he would be as much of a misfit on Krypton as Zahn is. What we see as Superman's virtues would there be seen as Kal-El's weaknesses.

I agree that he'd share that sense of protectiveness and empathy toward the people of Krypton, but he'd be mocked for it and would be denied most opportunities to act on that feeling. And that isolation might have led to a very different personality than the one we know and love as Superman.

Nrama: Finally, thank you both so, so much for taking the time to talk to us. I want to leave on, what do you hope readers take away from House of El?

Gray: Thanks for talking with me! I hope readers take away a new view of Krypton, and can actually imagine themselves there--and can recognize the few, but real, parallels between their mistakes and our own.

Check out Newsarama's list of the best DC stories of all time.

Continued here:
Building a House of El with Claudia Gray and Eric Zawadzki - GamesRadar

New information is published almost daily about the coronavirus pandemic.

Since the beginning of the coronavirus pandemic, there have been many thousands of articles and commentaries published on almost every imaginable aspect of the SARS-Cov-2 virus and the COVID-19 pandemic it has caused. They have appeared online, in journals, on preprint servers, in newspapers, and on blogs. As much as we might try to keep up, there will always be important facts or developments we might have missed, so below are a few that should help us understand some of the nuances of the pandemic.

#1 THERE APPEARS TO BE AN IMPORTANT DIFFERENCE IN EFFICACY BETWEEN THE Pfizer-BioNTech AND Moderna COVID-19 VACCINES.

The difference pertains to the efficacy across different demographic groupsspecifically, people of different ages. According to theFDAs analysisof the Pfizer-BioNTech vaccine, in the clinical trials on almost 44,000 subjects, it was 95.0% effective in persons aged 16-55, and 93.8% effective in those over age 55that is, essentially the same. By contrast, regulatorsreviewof the clinical studies with the Moderna vaccine found a pronouncedage-dependent difference: The [Vaccine Efficacy] in participants 65 years of age appears to be lower than in younger adults 18 to <65 years (86.4% compared to 95.6%) (emphasis added).

That is shown in the indicated portion of this table, from anarticlein the New England Journal of Medicine that reported the results of Modernas clinical trials:

Thus, of every hundred people under age 65 vaccinated with the Moderna vaccine, we can expect that about five will fail to develop an immune response after the two shots; among those 65 or over, about 14 will not be successfully immunized. (The failure rate for the Pfizer-BioNTech vaccine was approximately five in a hundred for all age groups.) The numbers are small, but the bottom line is,if youre 65 or older and you have a choice, Id recommend that you get the Pfizer-BioNTech vaccine.

#2 VACCINES ABILITY TO PREVENT SYMPTOMATIC COVID-19 IS NOT THE SAME THING AS COMPLETELY PREVENTING THE ESTABLISHMENT OF INFECTION (WHICH IS CALLED STERILIZING IMMUNITY).

Because of how the trials were designed, efficacy was defined as a positive test for the SARS-CoV-2 virus genetic material (RNA) and at least one symptom, such as fever, cough, fatigue, or loss of taste or smell. But that doesnt rule out the possibility that people who are successfully vaccinated (no positive test for the virus and no symptoms) could become infected and spread the virus to other people. Given that possibility, and also (as discussed above) the reality that fewer than 100% of people given the shots will be protected,it is essential that we continue to practice the non-pharmaceutical preventive measures: masking, social distancing, frequent handwashing, and avoiding crowds in enclosed spaces.

Going forward, we will need to know about the impact of vaccines on virus transmission, but for that, we will need new clinical studies with contact tracing to monitor the spread from vaccinated and unvaccinated participants. (One suggestion, by biostatistician Natalie Dean, is to design such a study using college students, because they arent prioritized for [receiving vaccine under the Emergency Use Authorizations], and transmission is higher in congregate settings.)

#3 CORONAVIRUS VACCINES ARE NOT NEW.

Coronavirus infections are common in companion animals and economically important livestock andvaccines to prevent these infections have been widely employedin veterinary medicine for many years. They have been administered to dogs, cattle, pigs, and poultry. (The animal coronaviruses are sufficiently different from SARS-CoV-2 that the veterinary vaccines would not prevent COVID-19 in humans.) Themore than a dozen veterinary vaccineslicensed in North America have been developed with an array of technologies and platforms, including genetic engineeringbut none, as yet, with the messenger RNA technology (mRNA) used for the Pfizer-BioNTech and Moderna vaccines.

#4 THE NOVEL TECHNOLOGY TO MAKE THE APPROVED COVID-19 VACCINES ISNT FUNDAMENTALLY NEW.

Many reporters and commentators have dutifully noted that vaccines have traditionally been composed of killed or attenuated (weakened) viruses so that they can elicit an immune response without causing disease. The Pfizer-BioNTech and Moderna COVID-19 vaccines, however, are made with a genetic engineering technology called messenger RNA (mRNA), which acts in anovel way. When injected into a persons muscle, the mRNA is read by the cells protein-synthesizing machinery and gives rise to numerous copies of a version of the SARS-CoV-2 virus spike protein, which is on the surface of the virus and plays a key role in attaching to the hosts cells.

An understanding of this continuum of approaches to vaccination should help to demystify COVID-19 vaccines for the considerable number of people who may be hesitant about taking a novel vaccine developed and approved in record time.

Those proteins elicit an immune response, so that if the person who has been injected subsequently comes into contact with the infectious SARS-CoV-2 virus, the bodys antibodies and immune cells are prepared to neutralize it.

However, theres a link missing in that narrative about the continuum from traditional vaccine development techniques to mRNAnamely, subunit vaccines, which are conceptually similar to using mRNA for vaccines. A good example is Mercks hepatitis B vaccineRecombivax, which has been around for more than 30 years. What is injected and stimulates the immune response in that case is a non-infectious viral protein that is synthesized in genetically engineered bakers yeast grown in huge fermentation vats. The protein, which is analogous to the coronavirus spike protein, is purified and used as the active substance in the vaccine.

A similar example is GlaxoSmithKlines shingles vaccineShingrix, which contains a glycoprotein (a protein linked to a carbohydrate) that is a component of the varicella zoster virus, and which is synthesized in genetically engineered Chinese hamster ovary cells.

There is also a COVID-19 vaccine using this technology being developed by Maryland-based Novavax. It containsproteins produced in genetically engineered insect cellsthat resemble the spike proteins found on the surface of the coronavirus, and which elicit an immune response after being injected.

The Merck, GlaxoSmithKline, and Novavax subunit vaccines are something of an intermediate approach between the killed or attenuated vaccines and the mRNA ones because the antigen injected is a protein, whereas the mRNA vaccines cause a protein to be synthesized in the vaccine recipient after injection. An understanding of this continuum of approaches to vaccination should help to demystify COVID-19 vaccines for the considerable number ofpeople who may be hesitantabout taking a novel vaccine developed and approved in record time.

#5 THE MONOCLONAL ANTIBODY DRUGS TO TREAT COVID-19 ARE GOING BEGGING.

In November, the FDA issued two Emergency Use Authorizations for monoclonal antibody drugs produced byEli LillyandRegeneron Pharmaceuticals, respectively, that treat mild to moderate cases of COVID-19 in adults and older pediatric patients at high risk for progressing to severe illness. They are expensive, and in short supply, but paradoxically, U.S. health officials are seeing a lack of demand for these drugs that can help to keep infected people out of the hospital.

If you are diagnosed with COVID-19, have symptoms, and qualify for these [monoclonal antibody] drugs, insist on getting them immediately.

Testing delays (they need to be infused intravenously within 10 days of the onset of symptoms), red tape, and shortages of staff for intravenous administration arepreventing many patientsfrom getting these drugs, which consist of laboratory-produced antibodies that mimic those produced in response to infection. ThisWall Street Journal headlinesays it all: Highly Touted Monoclonal Antibody Therapies Sit Unused in Hospitals.

There is an important news you can use message here:If you are diagnosed with COVID-19, have symptoms, and qualify for these drugs, insist on getting them immediately.

#6 THE NEW, MORE INFECTIOUS U.K. SARS-CoV-2 VARIANT (B.1.1.7) IS MORE DANGEROUS, EVEN IF NOT MORE VIRULENT.

Much of the reporting about this new variant of the SARS-CoV-2 virus, B.1.1.7, which has quickly become the predominant strain in parts of the U.K. and has now been detected in about three dozen other countries worldwide, including in various parts of the United States, has characterized it asmore transmissible, but not more deadly. Preliminary analyses suggest it isin the range of 56%-70% more transmissiblethan other circulating SARS-CoV-2 strains. However, that characterization is misleading in two respects.

First, the more transmissible the virus is, greater numbers of people will be infected and will be hospitalized, and morein the sense of absolute numberswill die. Thus,although perhaps not more likely to kill a particular individual who becomes infected, overall, the death toll from the viral variant will be higher because of its ability to infect more people.

Second, as World Health Organization epidemiologist Maria Van Kerkhovehas pointed out, The more of this virus circulates [because of greater transmissibility], the more opportunity it will have to change to something worse. She concluded, Were playing a very dangerous game here.

#7 WHEN SOMEBODY TELLS YOU THAT ITS SILLY TO IMPOSE LOCKDOWNS OR TAKE VACCINES BECAUSE OF AN ILLNESS WITH A SURVIVAL RATE OF 99.9%, YOURE ABOUT TO BE SOLD A BILL OF GOODS.

First of all, a conservative estimate of the death rate is not 0.1% (which would correspond to a survival rate of 99.9%), but probably well above 0.2%. That might not sound like a lot, but when applied to a huge number of cases, it can be catastrophicas it has been: COVID-19 haskilled 375,000 Americans, been diagnosed in over 22 million, and certainly infected several times that number.

Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.

Second, herd immunity, the point at which a sufficiently large fraction of the population is immune to infection because of natural infection or vaccination and causes the pandemic to wane, is thought to be upwards of80%in the case of COVID-19.In the absence of vaccines, achieving herd immunity would require the infection of approximately 264 million Americans, which would result in an unimaginable death toll.

Moreover, deaths and death rates are far from the whole story. The persistence of symptoms for months after recovery from the acute illness of COVID-19 is common, even in people who have suffered only mild cases of illnesses.According to the Mayo Clinic, the most common persistent signs and symptoms are fatigue, shortness of breath, cough, joint pain, and chest pain; and the virus can damage the lungs, heart, and brain, which increases the risk of long-term health problems.

We have come a long way in understanding COVID-19, but much remains unknown. As British Prime Minister Winston Churchill said about World War II, at the end of 1942, Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning. As to the COVID-19 pandemic, the scientific and medical communities in the public and private sector will continue to produce important new products and knowledge so we can get to the end as quickly as possible. In the meantime, it is more important than ever to heed their advice about taking precautions toflatten the curve.

This post originally appeared at https://humanevents.com/2021/01/11/critical-but-little-known-facts-about-the-covid-19-pandemic/ and is reposted with permission from the author.

See the original post here:
Critical but Little-Known Facts About the COVID-19 Pandemic - Physician's Weekly

The integrated Translational Health Research Institute of Virginia, oriTHRIV, a National Institutes of Health-funded Clinical and Translational Research Award hub, has awarded $200,000 in pilot funding to five multi-institutional research projects in Virginia.

Teams of physicians, researchers and engineers at the University of Virginia, Virginia Tech, Inova Health System and Carilion Clinic were awarded the funds as part of the iTHRIV NIH-NCATS award UL1TR003015. Support of these early phase research projects will help accelerate the discovery of potential treatment options for Parkinsons disease, celiac disease and epilepsy, as well innovation in the fields of telemedicine and pediatric heart transplant.

The awarded pilot projects include:

Sana Syed, an assistant professor in theUVA School of MedicinesDepartment of Pediatrics, and Suchitra Hourigan,Inova Childrens Hospitalsvice chair of research and innovation, seek to determine if machine learning is useful in diagnosing celiac disease sub-types.

Currently, treatment and management of celiac disease involves a gluten-free diet and is not intended to help assess the specific risk of patients developing other diseases. Syed and Hourigan will investigate gut tissue biopsies as well as genetic markers of patients with celiac disease and type 1 diabetes and/or hypothyroidism. They aim to determine whether biopsy or gene markers at the time of disease diagnosis can predict the risk of developing these diseases in the future.

The team will use machine learning algorithms to analyze multiple datasets. If successful, the team members hope that any patterns found will enable them to link biopsies and unique genes, paving the way for improved care for patients with celiac disease.

In most instances, how medications act on the brain to produce their therapeutic effect (for instance, pain relief) is not well understood. Aashit Shah, a professor of internal medicine at theVirginia Tech Carilion School of Medicine, and Sujith Vijayan, an assistant professor in the Virginia Tech College of SciencesSchool of Neuroscience, will study patients with intractable epilepsy who have been implanted with electrodes to determine the region responsible for their seizures.

The team will study signals measured in epileptic patients undergoing intracranial electroencephalography. They will review intracranial electrical signals from various brain regions following administration of medications that work on the brain. Shah and Vijayan hope to improve the understanding of how and where these medications work.

They anticipate this can help in the development of new biomarkers for neuroactive drugs, which may improve development of medications in the future.

Della Williams, a neurologist atCarilion Clinicand an assistant professor of internal medicine at the Virginia Tech Carilion School of Medicine, has also partnered with Vijayan to study auditory therapy for patients living with Parkinsons disease. Their project seeks to better understand the disease progression and if it can be slowed by providing background noise to patients as they sleep.

Additionally, simple auditory stimulation during sleep may help to improve learning and memory processes.

Elham Morshedzadeh, an assistant professor of industrial design in Virginia TechsCollege of Architecture and Urban Studies; Andre Muelenaer, a professor ofbiomedical engineering and mechanicsin Virginia Techs College of Engineering and a professor of pediatrics for the Virginia Tech Carilion School of Medicine; and Melinda Schriver, Carilions director of digital health, have proposed a study to design a successful and comprehensive telemedical encounter for infants and preschool children.

Theyll seek to provide a robust, feasible and affordable training program integrating augmented reality, online and hands-on learning experiences. The study aims to make telemedical encounters vastly more inclusive and efficient.

Heart transplantation is the standard of care for pediatric patients with end-stage heart failure or inoperable congenital defects, yet nearly 20% of patients die while on the waiting list.

To help increase the odds of successful pediatric heart transplants, Michael McCulloch, an associate professor and a pediatric cardiologist atUVA Childrens Hospital Heart Center, and Michael Porter, an associate professor of systems engineering inUVAs School of Engineering and Applied Science, will analyze donor echocardiographic data to identify which donor characteristics contribute to positive heart transplant recipient outcomes.

iTHRIV is a cross-state translational research institute which combines the expertise of clinical translational biomedical researchers and data scientists to create infrastructure and investigator resources for using data to improve health across the Commonwealth of Virginia. Partner sites include University of Virginia, Virginia Tech, Carilion Clinic and Inova Health System.

For more information about the NIH CTSA program, seehttps://ncats.nih.gov/ctsa

For more information about iTHRIV, seehttp://ithriv.org/

Read more:
iTHRIV Distributes $200000 to Fund Innovative Medical Research Projects - UVA Today

DUBLIN--(BUSINESS WIRE)--The "2020 Growth Opportunities in Plastic Degradation, Self-Healing Concrete, Hydrogen Production, and Software Inspection Tools" report has been added to ResearchAndMarkets.com's offering.

This edition of the Inside R&D Technology Opportunity Engine (TOE) covers development of novel devices that overcomes the traditional limitations of pressure sensors, design and development of low cost graphene filters for efficient capturing of waste gases from industrial exhaust stream, and the use of genetic engineering for the development of safer polio vaccines.

The TOE also features information on the design and synthesis of electro catalysts that can be used in rechargeable batteries and the utilization of hydrolysis process for enhancing the chemical degradation of polyester.

The Inside R&D TOE focuses on innovations associated with the use of novel neuro stimulation-based implants for treatment of chronic pain and the latest innovations enabling cost-effective use of bio-controls for minimizing pest attacks and crop diseases. The TOE additionally provides insights on the use of self-healing materials that enhance the durability and shelf life of concrete structures.

Key Topics Covered:

For more information about this report visit https://www.researchandmarkets.com/r/h6mmoy

Read more here:
Growth Opportunities in Plastic Degradation, Self-Healing Concrete, Hydrogen Production, and Software Inspection Tools, 2020 Report -...